BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
토요일, 9월 26

Bio-Techne Corp

TECHNASDAQ
Trade with Public
Trade with Public
$72.61
0.040.06%
가까이에: Sep 25, 5:00 PM EST
$72.61
N/A
시간외: 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황배당금비교옵션주식 보고서

Bio-Techne Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bio-Techne (TECH).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

3Buy
9Hold
Consensus RatingBuy# Analysts12Avg. Consensus PT$72Upside to Avg. PT-0.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026Wells FargoEvan StamplerDowngradeOverweight→Equal-Weight$62→$73
Jul 9, 2026RBC CapitalDan LeonardDowngradeOutperform→Sector Perform$62→$73
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.
Benzinga Newsdesk

PRO
RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73

RBC Capital analyst Dan Leonard downgrades Bio-Techne (NASDAQ:TECH) from Outperform to Sector Perform and raises the price target from $62 to $73.
Benzinga Newsdesk

PRO
TD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73

TD Cowen analyst Kyle Boucher downgrades Bio-Techne (NASDAQ:TECH) from Buy to Hold and raises the price target from $65 to $73.
Benzinga Newsdesk

PRO
Benchmark Downgrades Bio-Techne to Hold

Benchmark analyst Robert Wasserman downgrades Bio-Techne (NASDAQ:TECH) from Buy to Hold.
Benzinga Newsdesk

PRO
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73

Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.
Benzinga Newsdesk

PRO
Stephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

Stephens & Co. analyst Steven Etoch downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $68 to $73.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved